LC-MS / MS Adrenal Steroids Assayed on Dried Blot Spot for the Congenital Adrenal Hyperplasia Neonatal Screening (SPECTROSPOT)
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 16, 2018
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged between 48 and 120 hours of life.
- • Term of gestation: 30 to 41 weeks of gestation + 6 days
- • weight at inclusion ≥ 1000 g
- • non-opposition of the holders of parental authority
- Exclusion Criteria:
- • Patient who already had neonatal screening prior to inclusion.
- • Patients whose health status contraindicates additional blood collection at the time of neonatal screening.
- • Inability to give legal representatives of newborns informed information
- • Minor Parents
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, Ile De France, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials